[EN] DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES<br/>[FR] DÉRIVÉS D'AMIDES D'ACIDE 6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-CARBOXYLIQUE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2010141273A1
公开(公告)日:2010-12-09
Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I)
wherein Z is CH
2
or N—R
4
and X, R
1
, R
2
, R
4
, R
6
, R
7
and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
[EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
申请人:NOVARTIS AG
公开号:WO2014141104A1
公开(公告)日:2014-09-18
The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I)
wherein Z is CH
2
or N—R
4
and X, R
1
, R
2
, R
4
, R
6
, R
7
and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.